Track topics on Twitter Track topics that are important to you
Evecxia, Inc., a privately funded, clinical stage biopharmaceutical company, today announced that it has licensed exclusive, world-wide rights to develop and commercialize novel formulations for improving the bioavailability and pharmacokinetics of 5-hydroxytryptophan (5-HTP) from:
The joint intellectual property licensed from NUS-NUH-NTU was developed using funding from the National Health Innovation Centre Singapore (NHIC) under its Innovation to Develop (I2D) grant scheme.
“This license agreement with DUKE-NUS, NUH and NTUitive strengthens our patent portfolio with additional protection, geographic coverage, and years of exclusivity to EVX-101, our lead product candidate,” said John Kaiser, CEO of Evecxia.
Under the terms of the agreement, Evecxia will immediately assume full development and commercialization of EVX-101 and any other product candidates emanating from the license agreement with Duke-NUS, NUH and NTU. In addition to an upfront licensing fee Duke-NUS, NUH and NTU will receive milestone and low single-digit royalty payments.
Evecxia Inc. is a privately funded, clinical stage pharmaceutical company co-founded by Duke neuropsychopharmacologists, Dr. Marc Caron and Dr. Jacob Jacobsen. Evecxia is located in the Research Triangle Park, NC. Evecxia's primary mission is to develop and commercialize EVX-101 to treat patients suffering from disabling, common, and costly neuropsychiatric conditions in which current therapies, in many cases, are sub-optimal.
Evecxia is the first company dedicated to realizing the therapeutic potential of 5-HTP via specialized prescription combinations and drug delivery dosage forms.
EVX-101 is a proprietary oral slow-release formulation of 5-HTP and low-dose carbidopa. Initially, EVX-101 will be developed and positioned as a first-choice adjunctive treatment in depressed patients responding inadequately to conventional antidepressants. As an antidepressant, the development of EVX-101, a new chemical entity (NCE), is uniquely de-risked because the therapeutic mechanism—elevating extracellular serotonin beyond the effect of conventional SSRI/SNRI antidepressants—enjoys human proof-of-concept (POC) for efficacy and safety.
John Kaiser, CEO
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...